[1]林丽慧,唐 梅,于春玲,等.HPV阳性宫颈癌和CIN患者血浆miR-150,SCCA及CA125的表达及临床意义[J].现代检验医学杂志,2018,33(02):62-65，69.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIN Li-hui,TANG Mei,YU Chun-ling,et al.Expression and Clinical Significance of Plasma miR-150,SCCA and CA125 in Patients with HPV Positive Cervical Cancer and CIN[J].Journal of Modern Laboratory Medicine,2018,33(02):62-65，69.[doi:10.3969/j.issn.1671-7414.2018.02.001]
点击复制

HPV阳性宫颈癌和CIN患者血浆miR-150,SCCA及CA125的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年02期
页码:
62-65，69
栏目:
论著
出版日期:
2018-04-05

文章信息/Info

Title:
Expression and Clinical Significance of Plasma miR-150,SCCA and CA125 in Patients with HPV Positive Cervical Cancer and CIN
文章编号:
1671-7414(2018)02-062-05
作者:
林丽慧; 唐 梅; 于春玲; 林万妹
海南西部中心医院妇产科,海南那大 571799
Author(s):
LIN Li-hui; TANG Mei; YU Chun-ling; LIN Wan-mei
Obstetrics and Gynecology Department, Hainan West Central Hospital,Hainan Nada 571799,China
关键词:
miR-150;  宫颈癌;  宫颈上皮内瘤样病变;  人乳头瘤病毒;  诊断价值
分类号:
R737.33; R730.43
DOI:
10.3969/j.issn.1671-7414.2018.02.001
文献标志码:
A
摘要:
目的 探讨血浆miR-150,鳞状细胞癌抗原(SCCA)及糖类抗原125(CA125)在人乳头瘤病毒(HPV)阳性宫颈癌患者中的表达及临床意义。方法采用RT-PCR检测108例HPV阳性宫颈癌患者(宫颈癌组),40例HPV阳性宫颈上皮内瘤变(CIN)患者(CIN组)和40例HPV单纯阳性/HPV阳性子宫良性病变者(对照组)血浆miR-150,SCCA及CA125水平,分析miR-150表达与宫颈癌临床病理特征的关系。应用ROC曲线评价miR-150,SCCA及CA125在HPV阳性宫颈癌患者中的早期诊断价值,多元Logistic回归模型分析三项指标与HPV阳性宫颈癌的关系。结果 宫颈癌组血浆miR-150,SCCA及CA125表达水平均明显高于CIN组和对照组[miR-150(2-ΔΔCt):10.28±4.16,4.72±1.18和1.83±0.64; SCCA(ng/ml):9.86±2.14,3.18±0.85和1.35±0.34; CA125(U/ml):46.26±11.58,19.14±7.05和16.42±5.83,F=16.427,13.205,8.719,均P<0.01]。HPV阳性宫颈癌患者血浆miR-150表达水平与临床分期、淋巴结转移及浸润深度相关(P<0.05)。血浆miR-150诊断HPV阳性宫颈癌和CIN的最佳截值分别为8.25和3.46,敏感度和特异度分别为87.0%和84.3%,81.0%和80.2%。Logistic回归分析显示,血浆miR-150和SCCA水平升高是HPV阳性宫颈癌发生的独立危险因素[OR(95%CI)=2.107(1.915～2.814),OR(95%CI)=1.583(1.327～2.036)]。结论 血浆miR-150在HPV阳性宫颈癌患者中明显上调,可作为HPV阳性宫颈癌早期诊断和CIN鉴别诊断的生物学标志物。
Abstract:
Abstract:Objective To investigate the expression and clinical significance of plasma miR-150,squamous cell carcinoma antigen(SCCA)and carbohydrate antigen 125(CA125)in human papillomavirus(HPV)positive cervical cancer patients.Methods RT-PCR was detected in 108cases of HPV patients with positive cervical cancer(cervical cancer group)and40 cases of HPV positive CIN patients(CIN group)and 40 cases of HPV with positive/HPV positive uterine benign lesions(control group),plasma miR-150,SCCAand CA125 levels.Analyzed the relation between miR-150 expression and clinicopathological features of cervical cancer.ROC curve was used to evaluate the early diagnostic value of miR-150,SCCA and CA125 in patients with HPV positive cervical cancer.Multivariate Logistic regression model was used to analyze the relationship between three indicators and HPV positive cervical cancer.Results The levels of miR-150,SCCA and CA125 in the cervical cancer group were significantly higher than those in the CIN group and the controlgroup [miR-150(2-ΔΔCt):10.28±4.16 vs 4.72±1.18 and 1.83±0.64.SCCA(ng/ml):9.86±2.14 vs 3.18±0.85 and 1.35±0.34.CA125(U/ml):46.26±11.58 vs 19.14±7.05 and 16.42±5.83,F=16.427,13.205,8.719,all P<0.01].The expression of plasma miR-150 in HPV positive cervical cancer correlated with clinical stage,lymph node metastasis and depth of invasion(P<0.05).The optimalcut-off values of plasma miR-150 for diagnosis of HPV positive cervical cancer and CIN were 8.25 and 3.46,and the sensitivity and specificity were 87.0%and 84.3%,81.0% and 80.2%,respectively.Logistic regression analysis showed that elevated plasma miR-150 and SCCA levels were independent risk factors for HPV positive cervical cancer [OR(95%CI)=2.107(1.915～2.814),OR(95%CI)=1.583(1.327～2.036)].Conclusion Plasma miR-150 was significantly up-regulated in patients with HPV positive cervical cancer,which canbe used as a biological marker for the early diagnosis of HPV positive cervicalcancer and the differential diagnosis of CIN.

参考文献/References:

[1] Mi Y,Wang L,Zong L,et al.Genetic variants in microRNA targetsites of 37 selected cancer-related genes and the risk of cervical cancer[J].PLoS One,2014,9(1):e86061.
[2] 杨 辉,郑 君.联合检测血清SCCA,CA19-9及CA125对宫颈癌诊断及预后判断的临床意义[J].中国妇幼保健,2013,28(5):772-774. Yang H,Zheng J.Clinical significance of joint detection ofserum SCCA,CA19-9 and CA125 for diagnosis and prognosis evaluation of cervical cancer[J].Matern Child Health Care of China,2013,28(5):772-774.
[3] Liu DZ,Zhang HY,Long XL,et al.MIR-150 promotes prostate cancer stemcell development via suppressing p27Kip1[J].Eur Rev Med Pharmacol Sci,2015,19(22):4344-4352.
[4] Sarlinova M,Halasa M,Mistuna D,et al.MiR-21,miR-221 and miR-150 are deregulated in peripheral blood of patients with colorectal cancer[J].Anticancer Res,2016,36(10):5449-5454.
[5] Li JH,Sun SS,Li N,et al.MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer[J].Oncotarget,2017,8(54):91938-91949.
[6] Zhao XL,Hu SY,Zhang Q,et al.High-risk human papillomavirus genotypedistribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population[J].J Gynecol Oncol,2017,28(4):e30.
[7] Yan J,Li X,Peng L,et al.MicroRNA-150 as a potential biomarker in diagnosis of cancer:a meta-analysis[J].Clin Lab,2017,63(7):1187-1197.
[8] Yin QW,Sun XF,Yang GT,et al.Increased expression of microRNA-150 isassociated with poor prognosis in non-small cell lung cancer[J].Int J Clin Exp Pathol,2015,8(1):842-846.
[9] Ghose J,Bhattacharyya NP.Transcriptional regulation of microRNA-100,-146a,and -150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/Hdh(Q7)cells and human cervical carcinoma HeLa cells[J].RNA Biol,2015,12(4):457-477.
[10] 李 均,冯 露,徐 凡,等.miR-150在宫颈癌组织中的表达及临床意义[J].现代肿瘤医学,2017,25(21):3487-3490. Li J,Feng L,Xu F,et al.The expression and clinical significance of miR-150 in cervical cancer tissue[J].Modern Oncology,2017,25(21):3487-3490.
[11] Li J,Hu L,Tian C,et al.MicroRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4[J].BMC Mol Biol,2015,16(12):24.
[12] Wang X,Wang HK,Li Y,et al.MicroRNAs are biomarkers of oncogenic human papillomavirus infections[J].Proc Natl Acad Sci USA,2014,111(11):4262-4267.
[13] Liu P,Xin F,Ma CF.Clinical significance of serum miR-196a in cervical intraepithelial neoplasia and cervical cancer[J].Genet Mol Res,2015,14(4):17995-18002.
[14] Liang H,Li Y,Luo RY,et al.MicroRNA-215 is a potential prognostic marker for cervical cancer[J].J Huazhong Univ Sci Technolog Med Sci,2014,34(2):207-212.
[15] He Y,Lin J,Ding Y,et al.A systematic study on dysregulated microRNAsin cervical cancer development[J].Int J Cancer,2016,138(6):1312-1327.
[16] Ma Y,Zhang P,Wang F,et al.MiR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer[J].Gut,2012,61(10):1447-1453.

相似文献/References:

[1]王 妍,黄钦贤,林章礼,等.汕头地区女性HPV的感染状况回顾[J].现代检验医学杂志,2015,30(04):122.[doi:10.3969/j.issn.1671-7414.2015.04.036]
　WANG Yan,HUANG Qin-xian,LIN Zhang-li,et al.Review of HPV Infection Status of the Women in Shantou Region[J].Journal of Modern Laboratory Medicine,2015,30(02):122.[doi:10.3969/j.issn.1671-7414.2015.04.036]
[2]原荣,李军,王一羽,等.陕西省榆林地区和商洛地区HPV感染及亚型分布对比研究[J].现代检验医学杂志,2016,31(06):48.[doi:10.3969/j.issn.1671-7414.2016.06.013]
　YUAN Rong,LI Jun,WANG Yi-yu,et al.Study on HPV Infection Rate and Hypotype Distribution between Yulin and Shangluo Area in Shaanxi Province[J].Journal of Modern Laboratory Medicine,2016,31(02):48.[doi:10.3969/j.issn.1671-7414.2016.06.013]
[3]王 冰,朱月蓉,何玉杰,等.血清结合珠蛋白在宫颈癌诊断中的应用研究[J].现代检验医学杂志,2017,32(01):106.[doi:10.3969/j.issn.1671-7414.2017.01.029]
　WANG Bing,ZHU Yue-rong,HE Yu-jie,et al.Application of Haptoglobin in Cervical Cancer Diagnosis[J].Journal of Modern Laboratory Medicine,2017,32(02):106.[doi:10.3969/j.issn.1671-7414.2017.01.029]
[4]原 荣,李 军,南 星,等.陕西省安康和延安两地区妇女HPV感染及型别分布对比研究[J].现代检验医学杂志,2017,32(02):64.[doi:10.3969/j.issn.1671-7414.2017.02.017]
　YUAN Rong,LI Jun,NAN Xing,et al.Comparative Study on HPV Infection and Hypotype Distribution between Ankang and Yan'an Area of Shaanxi Province[J].Journal of Modern Laboratory Medicine,2017,32(02):64.[doi:10.3969/j.issn.1671-7414.2017.02.017]
[5]林金端a,刘红伟a,张欣宁b,等.Mybl2在不同病变程度宫颈组织中的表达[J].现代检验医学杂志,2017,32(02):141.[doi:10.3969/j.issn.1671-7414.2017.02.039]
　LIN Jin-duana,LIU Hong-weia,ZHANG Xin-ningb,et al.Expression Level and Clinical Significance of Mybl2 in Cervical Tissues[J].Journal of Modern Laboratory Medicine,2017,32(02):141.[doi:10.3969/j.issn.1671-7414.2017.02.039]
[6]冯 磊,常春红,管晓卿,等.宫颈癌患者血浆miRNA-10b的表达及其临床意义[J].现代检验医学杂志,2018,33(01):52.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　FENG Lei,CHANG Chun-hong,GUAN Xiao-qing,et al.Expression of Plasma miRNA-10b in Patients with Cervical Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(02):52.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘 娅,贺 巧,佘佳琪.宫颈癌患者治疗前血浆凝血四项指标与生存率的相关性研究[J].现代检验医学杂志,2019,34(03):137.[doi:10.3969/j.issn.1671-7414.2019.03.035]
　LIU Ya,HE Qiao,SHE Jia-qi.Correlation between the Four Indicators of Coagulation andPrognosis in Patients with Cervical Carcinoma before Treatment[J].Journal of Modern Laboratory Medicine,2019,34(02):137.[doi:10.3969/j.issn.1671-7414.2019.03.035]

备注/Memo

备注/Memo:
作者简介:林丽慧(1981-),女,本科,主治医师,主要从事临床妇产科疾病研究,E-mail:linlihui028@163.com。 通讯作者:唐 梅(1964-),女,本科,副主任医师,主要从事临床妇产科疾病研究,E-mail:13976127612@139.com。
更新日期/Last Update: 2018-04-16